Mysteries of Myeloma

A series of 5 FREE to attend weekly educational webinars, provided by UK NEQAS Immunology, Immunochemistry & Allery (IIA), in collaboration with Myeloma UK.

And Finally...

Week 5: Participants Questions and Tricky Cases - Summary/Discussion

The final session of the Mysteries of Myeloma webinar series will focus on summarising the learning points from the previous webinars and answering any questions attendees may have. This session will provide a forum for discussion with the speaker panel regarding any aspect of diagnosis, treatment or monitoring of Myeloma. There will also be an opportunity for attendees to obtain interpretation guidance from the speaker panel for any laboratory aspects e.g. “difficult” gels to interpret or unusual result profile.

Date: Wednesday 19th May 2021

Time: 15:30-16:30 (UK)

Duration: 60 minutes

Speakers: Dina Patel and Speaker Panel

Other sessions in the Mysteries of Myeloma webinar series have been:

Week 1: What is Myeloma and the Patient's Perspective?

Speakers: Dr Fenella Willis and Mark Scott

Date: Wednesday 21st April 2021 - THIS SESSION HAS NOW BEEN DELIVERED

This session is about the diagnosis of Myeloma and the impact of delayed diagnosis, an overview of treatment and monitoring. Mark will be providing insight into the patient experience and the impact delayed diagnosis has had on a personal level.    

Weeks 2 & 3: Diagnostic Testing for Myeloma - Challenges and Pitfalls

Speaker: Dr Joanna Sheldon

Date: Wednesday 28th April and Wednesday 5th May 2021 - THESE SESSIONS HAVE NOW BEEN DELIVERED

Session 2 and session 3 of the Mysteries of Myeloma webinar series will look at what we should be doing in the “proteins” sections of labs.  We will look at the pre-analytical issues and try to give the delegates some guidance on sensible reasons to request protein electrophoresis and immunoglobulins, we will look at the analytical requirements for the measurement of immunoglobulin, total protein and serum free light chains.   The requirement of serum and urine protein electrophoresis and immunofixation and their interpretation will be illustrated with examples. Finally, we will look at the post analytical issues including how we put all the results together into a useful comment for the requesting clinician and when to communicate results rapidly.  

Week 4: New Monoclonal Gammopathy Patient, Now What?

Speaker: Dr Ross Sadler

Date: Wednesday 12th May 2021 - THIS SESSION HAS NOW BEEN DELIVERED

Identification of a patient's monoclonal status, using serum and urine is critical to the beginning of monoclonal gammopathy care.  Part of this process is being able to determine the significance of any new monoclonal that is discovered.  In this session, we will be focusing on how we can risk stratify new monoclonal gammopathy patients and work alongside Clinical Haematology and primary care to improve referral and monitoring processes.